Why the study?
The role of renal sympathetic denervation in cardiovascular disease has been an ongoing debate since initial results, despite a strong biological rationale.
Does renal sympathetic denervation provide therapeutic benefit in patients with cardiovascular diseases such as hypertension, arrhythmias, and heart failure?
Does renal sympathetic denervation provide therapeutic benefit in patients with cardiovascular diseases such as hypertension, arrhythmias, and heart failure?
This review summarizes the existing evidence and future perspectives for renal sympathetic denervation as a treatment option for cardiovascular diseases driven by sympathetic overactivity.
Renal denervation may benefit select patients with sympathetic-driven disease; leaves open its clinical role pending definitive trials.
The role of renal sympathetic denervation (RDN) has been the topic of ongoing debate ever since the impressive initial results. The rationale of RDN is strong and supported by non-clinical studies, which lies in uncoupling the autonomic nervous crosstalk between the kidneys and the central nervous system. Since we know that cardiovascular diseases, such as hypertension, atrial, ventricular arrhythmias and heart failure (HF) are related to sympathetic (over)activity, modulation of the renal nerve activity appears to be a reasonable and attractive therapeutic target in these patients. This review will focus on the existing evidence and potential future perspectives for RDN as treatment option in cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Hoogerwaard et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: